Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 19/20 | 0.48 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.47 |
| ▸ | PDE4A | P27815 | 1/20 | 0.47 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.47 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.47 |
| ▸ | CNR1 | P21554 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1433277 | 1.00 | CNR2 (0.48) | CNR2ABCB11PDE4APDE4BPDE4C | |
| SCHEMBL17207630 | 0.90 | CNR2 (0.49) | CNR2ABCB11PDE4APDE4BPDE4C | |
| SCHEMBL15764316 | 0.88 | CNR2 (0.47) | CNR2ABCB11PDE4APDE4BPDE4C | |
| SCHEMBL72985 | 0.88 | PDE4D (0.59) | CNR2ABCB11PDE4APDE4BPDE4C | |
| SCHEMBL17207628 | 0.83 | PDE4A (0.43) | CNR2PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL17201804 | 0.83 | PDE4D (0.55) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL17207625 | 0.82 | PDE4A (0.42) | CNR2PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL15397615 | 0.82 | PDE4A (0.43) | CNR2ABCB11PDE4APDE4BPDE4C | |
| SCHEMBL1978878 | 0.82 | CNR2 (0.50) | CNR2CNR1 | |
| SCHEMBL1978884 | 0.81 | ABCB11 (0.46) | CNR2ABCB11PDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025080415-A1 | TREATMENT OF NEUROPSYCHIATRIC DISORDERS WITH TILIVAPRAM | ALTO NEUROSCIENCE, INC. (US) | 2025-04-17 | — | — | WO | disclosed |
| EP-4281065-A1 | ENHANCEMENT OF CAMP SIGNALING AS A COMBINATION DRUG STRATEGY FOR THE TREATMENT OF DEPRESSION AND RELATED CONDITIONS | Alto Neuroscience, Inc. (US) | 2023-11-29 | — | — | EP | disclosed |
| WO-2022159632-A1 | ENHANCEMENT OF CAMP SIGNALING AS A COMBINATION DRUG STRATEGY FOR THE TREATMENT OF DEPRESSION AND RELATED CONDITIONS | ALTO NEUROSCIENCE, INC. (US) | 2022-07-28 | — | — | WO | disclosed |